He further said with the advent of quality concerns raised by global regulatory agencies, Pharmexcil’s priority has been shifted to quality management and imbibing quality culture in the industry by way of organising capacity building programmes in states to uphold the image of Indian pharma on global platform.
According to the pharma exports body, India has 748 US Food and Drug Administration approved manufacturing facilities.
He also said the Indian pharma sector is fraught with challenges such as geopolitical tensions, supply chain issues, pricing pressures and increased scrutiny by global regulatory agencies, among others and that the government needs to be proactive to overcome these hurdles.
“During 2023-29, 15 blockbuster drugs (including biological products) are going to be off-patented worth USD 112 billion which would provide a tremendous growth opportunity for India pharmaceutical companies by another USD 10 billion,” the official said.
A senior official of the Pharmexcil said drugs such as Merck’s Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb’s Eliquis (Apixaban)-USD 12 billion, among others would be off-patented in the next few years. According to him, Indian pharma exports grew from USD 3.9 billion in FY05 to USD 27.85 billion in FY24 and is expected to touch around USD 31 billion this fiscal. Bhaskar said India’s imports during April and May have increased marginally by 1.98 per cent, from USD 8.10 billion in FY23 to USD 8.26 billion in FY24.
According to him, Latin America and Africa are the focussed geographies for Indian pharma exports.
